Amneal Pharmaceuticals (NASDAQ:AMRX) Director John Kiely Sells 50,000 Shares of Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director John Kiely sold 50,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the sale, the director owned 210,252 shares of the company’s stock, valued at $3,708,845.28. This represents a 19.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Amneal Pharmaceuticals Trading Up 5.1%

AMRX traded up $0.88 during midday trading on Friday, reaching $18.15. 2,006,321 shares of the company were exchanged, compared to its average volume of 2,167,094. The stock has a market capitalization of $5.79 billion, a P/E ratio of 37.04 and a beta of 1.27. Amneal Pharmaceuticals, Inc. has a one year low of $9.20 and a one year high of $19.26. The stock’s 50-day simple moving average is $17.15 and its 200 day simple moving average is $14.56. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AMRX. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. The Goldman Sachs Group restated a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. UBS Group raised their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Barclays lifted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $17.67.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Amneal Pharmaceuticals by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock worth $793,000 after buying an additional 4,178 shares during the period. Millennium Management LLC raised its position in Amneal Pharmaceuticals by 32.6% in the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock valued at $17,492,000 after buying an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Amneal Pharmaceuticals in the 1st quarter valued at approximately $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Amneal Pharmaceuticals by 5.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock worth $2,807,000 after acquiring an additional 16,536 shares during the last quarter. Finally, Creative Planning boosted its position in Amneal Pharmaceuticals by 61.9% during the 2nd quarter. Creative Planning now owns 23,896 shares of the company’s stock worth $193,000 after acquiring an additional 9,136 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.